Switch theme
Sign up to access all valuation multiples
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
1995
183
LTM Revenue $56.0M
LTM EBITDA -$72.9M
$114M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sangamo Therapeutics has a last 12-month revenue (LTM) of $56.0M and a last 12-month EBITDA of -$72.9M.
In the most recent fiscal year, Sangamo Therapeutics achieved revenue of $57.8M and an EBITDA of -$89.1M.
Sangamo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sangamo Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $56.0M | XXX | $57.8M | XXX | XXX | XXX |
| Gross Profit | $56.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$72.9M | XXX | -$89.1M | XXX | XXX | XXX |
| EBITDA Margin | -130% | XXX | -154% | XXX | XXX | XXX |
| EBIT | -$97.6M | XXX | -$98.4M | XXX | XXX | XXX |
| EBIT Margin | -175% | XXX | -170% | XXX | XXX | XXX |
| Net Profit | -$93.5M | XXX | -$97.9M | XXX | XXX | XXX |
| Net Margin | -167% | XXX | -169% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sangamo Therapeutics's stock price is $0.
Sangamo Therapeutics has current market cap of $114M, and EV of $114M.
See Sangamo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $114M | $114M | XXX | XXX | XXX | XXX | $-0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sangamo Therapeutics has market cap of $114M and EV of $114M.
Sangamo Therapeutics's trades at 2.0x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Sangamo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sangamo Therapeutics has a P/E ratio of -1.2x.
See valuation multiples for Sangamo Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSangamo Therapeutics's last 12 month revenue growth is -10%
Sangamo Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Sangamo Therapeutics's rule of 40 is -65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sangamo Therapeutics's rule of X is -156% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sangamo Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | -11% | XXX | XXX | XXX |
| EBITDA Margin | -130% | XXX | -154% | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -65% | XXX | -165% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -156% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 193% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 270% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sangamo Therapeutics acquired XXX companies to date.
Last acquisition by Sangamo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sangamo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sangamo Therapeutics founded? | Sangamo Therapeutics was founded in 1995. |
| Where is Sangamo Therapeutics headquartered? | Sangamo Therapeutics is headquartered in United States of America. |
| How many employees does Sangamo Therapeutics have? | As of today, Sangamo Therapeutics has 183 employees. |
| Who is the CEO of Sangamo Therapeutics? | Sangamo Therapeutics's CEO is Dr. Alexander Donald Macrae, M.B.,PhD. |
| Is Sangamo Therapeutics publicy listed? | Yes, Sangamo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sangamo Therapeutics? | Sangamo Therapeutics trades under SGMO ticker. |
| When did Sangamo Therapeutics go public? | Sangamo Therapeutics went public in 2000. |
| Who are competitors of Sangamo Therapeutics? | Similar companies to Sangamo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sangamo Therapeutics? | Sangamo Therapeutics's current market cap is $114M |
| What is the current revenue of Sangamo Therapeutics? | Sangamo Therapeutics's last 12 months revenue is $56.0M. |
| What is the current revenue growth of Sangamo Therapeutics? | Sangamo Therapeutics revenue growth (NTM/LTM) is -10%. |
| What is the current EV/Revenue multiple of Sangamo Therapeutics? | Current revenue multiple of Sangamo Therapeutics is 2.0x. |
| Is Sangamo Therapeutics profitable? | Yes, Sangamo Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sangamo Therapeutics? | Sangamo Therapeutics's last 12 months EBITDA is -$72.9M. |
| What is Sangamo Therapeutics's EBITDA margin? | Sangamo Therapeutics's last 12 months EBITDA margin is -130%. |
| What is the current EV/EBITDA multiple of Sangamo Therapeutics? | Current EBITDA multiple of Sangamo Therapeutics is -1.6x. |
| What is the current FCF of Sangamo Therapeutics? | Sangamo Therapeutics's last 12 months FCF is -$63.7M. |
| What is Sangamo Therapeutics's FCF margin? | Sangamo Therapeutics's last 12 months FCF margin is -114%. |
| What is the current EV/FCF multiple of Sangamo Therapeutics? | Current FCF multiple of Sangamo Therapeutics is -1.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
